145 related articles for article (PubMed ID: 31871269)
21. Resistance to MAPK Inhibitors in Melanoma Involves Activation of the IGF1R-MEK5-Erk5 Pathway.
Benito-Jardón L; Díaz-Martínez M; Arellano-Sánchez N; Vaquero-Morales P; Esparís-Ogando A; Teixidó J
Cancer Res; 2019 May; 79(9):2244-2256. PubMed ID: 30833419
[TBL] [Abstract][Full Text] [Related]
22. Evolving role of entrectinib in treatment of
Chawla N; Bui NQ; Seetharam M
Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
[TBL] [Abstract][Full Text] [Related]
23. [Effects of tyrosine kinase receptor B and brain-derived neurotrophic factor on chemoresistance in neuroblastoma].
Li AM; Zhang JH; Zhang JH; Zhang KR; Rong DJ
Zhonghua Er Ke Za Zhi; 2006 Jul; 44(7):535-9. PubMed ID: 17044982
[TBL] [Abstract][Full Text] [Related]
24. Novel ALK inhibitor AZD3463 inhibits neuroblastoma growth by overcoming crizotinib resistance and inducing apoptosis.
Wang Y; Wang L; Guan S; Cao W; Wang H; Chen Z; Zhao Y; Yu Y; Zhang H; Pang JC; Huang SL; Akiyama Y; Yang Y; Sun W; Xu X; Shi Y; Zhang H; Kim ES; Muscal JA; Lu F; Yang J
Sci Rep; 2016 Jan; 6():19423. PubMed ID: 26786851
[TBL] [Abstract][Full Text] [Related]
25. Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma.
Eggert A; Ikegaki N; Liu XG; Brodeur GM
Klin Padiatr; 2000; 212(4):200-5. PubMed ID: 10994551
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK.
Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P
Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of MEK1/2 Forestalls the Onset of Acquired Resistance to Entrectinib in Multiple Models of NTRK1-Driven Cancer.
Vaishnavi A; Scherzer MT; Kinsey CG; Parkman GL; Truong A; Ghazi P; Schuman S; Battistone B; Garrido-Laguna I; McMahon M
Cell Rep; 2020 Aug; 32(5):107994. PubMed ID: 32755586
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.
Van Maerken T; Ferdinande L; Taildeman J; Lambertz I; Yigit N; Vercruysse L; Rihani A; Michaelis M; Cinatl J; Cuvelier CA; Marine JC; De Paepe A; Bracke M; Speleman F; Vandesompele J
J Natl Cancer Inst; 2009 Nov; 101(22):1562-74. PubMed ID: 19903807
[TBL] [Abstract][Full Text] [Related]
29. Resistance to chemotherapy mediated by TrkB in neuroblastomas.
Ho R; Eggert A; Hishiki T; Minturn JE; Ikegaki N; Foster P; Camoratto AM; Evans AE; Brodeur GM
Cancer Res; 2002 Nov; 62(22):6462-6. PubMed ID: 12438236
[TBL] [Abstract][Full Text] [Related]
30. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).
Drilon A; Siena S; Ou SI; Patel M; Ahn MJ; Lee J; Bauer TM; Farago AF; Wheler JJ; Liu SV; Doebele R; Giannetta L; Cerea G; Marrapese G; Schirru M; Amatu A; Bencardino K; Palmeri L; Sartore-Bianchi A; Vanzulli A; Cresta S; Damian S; Duca M; Ardini E; Li G; Christiansen J; Kowalski K; Johnson AD; Patel R; Luo D; Chow-Maneval E; Hornby Z; Multani PS; Shaw AT; De Braud FG
Cancer Discov; 2017 Apr; 7(4):400-409. PubMed ID: 28183697
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of EGFR and MEK surmounts entrectinib resistance in a brain metastasis model of NTRK1-rearranged tumor cells.
Suzuki C; Nishiyama A; Arai S; Tange S; Tajima A; Tanimoto A; Fukuda K; Takumi Y; Kotani H; Takeuchi S; Yanagimura N; Ohtsubo K; Yamamoto N; Omori K; Yano S
Cancer Sci; 2022 Jul; 113(7):2323-2335. PubMed ID: 35363931
[TBL] [Abstract][Full Text] [Related]
32. Entrectinib: First Global Approval.
Al-Salama ZT; Keam SJ
Drugs; 2019 Sep; 79(13):1477-1483. PubMed ID: 31372957
[TBL] [Abstract][Full Text] [Related]
33. The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.
Infarinato NR; Park JH; Krytska K; Ryles HT; Sano R; Szigety KM; Li Y; Zou HY; Lee NV; Smeal T; Lemmon MA; Mossé YP
Cancer Discov; 2016 Jan; 6(1):96-107. PubMed ID: 26554404
[TBL] [Abstract][Full Text] [Related]
34. Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo.
Li Z; Oh DY; Nakamura K; Thiele CJ
Cancer; 2011 Dec; 117(23):5412-22. PubMed ID: 21590687
[TBL] [Abstract][Full Text] [Related]
35. Identification of novel candidate compounds targeting TrkB to induce apoptosis in neuroblastoma.
Nakamura Y; Suganami A; Fukuda M; Hasan MK; Yokochi T; Takatori A; Satoh S; Hoshino T; Tamura Y; Nakagawara A
Cancer Med; 2014 Feb; 3(1):25-35. PubMed ID: 24403123
[TBL] [Abstract][Full Text] [Related]
36. A kinome-wide RNAi screen identifies ALK as a target to sensitize neuroblastoma cells for HDAC8-inhibitor treatment.
Shen J; Najafi S; Stäble S; Fabian J; Koeneke E; Kolbinger FR; Wrobel JK; Meder B; Distel M; Heimburg T; Sippl W; Jung M; Peterziel H; Kranz D; Boutros M; Westermann F; Witt O; Oehme I
Cell Death Differ; 2018 Dec; 25(12):2053-2070. PubMed ID: 29515255
[TBL] [Abstract][Full Text] [Related]
37. Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Russo M; Misale S; Wei G; Siravegna G; Crisafulli G; Lazzari L; Corti G; Rospo G; Novara L; Mussolin B; Bartolini A; Cam N; Patel R; Yan S; Shoemaker R; Wild R; Di Nicolantonio F; Bianchi AS; Li G; Siena S; Bardelli A
Cancer Discov; 2016 Jan; 6(1):36-44. PubMed ID: 26546295
[TBL] [Abstract][Full Text] [Related]
38. P53/PUMA are potential targets that mediate the protection of brain-derived neurotrophic factor (BDNF)/TrkB from etoposide-induced cell death in neuroblastoma (NB).
Hua Z; Zhan Y; Zhang S; Dong Y; Jiang M; Tan F; Liu Z; Thiele CJ; Li Z
Apoptosis; 2018 Aug; 23(7-8):408-419. PubMed ID: 29959561
[TBL] [Abstract][Full Text] [Related]
39. Annexin A2 could enhance multidrug resistance by regulating NF-κB signaling pathway in pediatric neuroblastoma.
Wang Y; Chen K; Cai Y; Cai Y; Yuan X; Wang L; Wu Z; Wu Y
J Exp Clin Cancer Res; 2017 Aug; 36(1):111. PubMed ID: 28814318
[TBL] [Abstract][Full Text] [Related]
40. Targeting TRK family proteins in cancer.
Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
